Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer 2/8/10
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells. The compounds were identified as part of the Company's ongoing oncology drug discovery efforts. The data are being presented in both oral and poster sessions at the American Association for Cancer Research (AACR) conference on Protein Translation and Cancer in Coronado, CA.
"Progenics' identification of these small-molecule compounds as part of our discovery program underscores our long-standing commitment to oncology drug development," stated Paul J. Maddon, M.D., Ph.D., Founder, Chief Executive Officer and Chief Science Officer of Progenics. "In laboratory studies, the synthetic, small-molecule compounds blocked both phosphoinositide 3-kinase (PI3K), which is a key regulator of one molecular signaling pathway, and MNK, an oncogenic kinase in the Ras pathway. We look forward to exploring the therapeutic potential of this series of compounds which are being optimized for clinical development."...
To view the complete article, please login or subscribe if you don't already have an account.